Citigroup’s Revance Therapeutics, Inc. RVNC Stock Holding History

Citigroup’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-28,000	Closed	-$246K	–	5888
2023 Q4	$246K	Hold	28,000	–	–	﹤0.01%	3829
2023 Q3	$321K	Hold	28,000	–	–	﹤0.01%	3371
2023 Q2	$709K	Sell	28,000 -25,000	-47%	-$779K	﹤0.01%	3109
2023 Q1	$1.71M	Sell	53,000 -565,000	-91%	-$17.6M	﹤0.01%	2126
2022 Q4	$11.4M	Buy	618,000 +32,600	+6%	+$746K	0.01%	1063
2022 Q3	$15.8M	Buy	+585,400	New	+$11.9M	0.01%	906
2022 Q1	–	Sell	-117,900	Closed	-$1.92M	–	6663
2021 Q4	$1.92M	Buy	+117,900	New	+$1.97M	﹤0.01%	2653

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup's RVNC Position: Q1 2025 in Review

Citigroup sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 90,172 shares — an estimated $274K sold.

Citigroup first reported a position in RVNC in Q1 2014 and held it in 44 quarters. The position peaked at $1.92M in Q3 2022. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

Citigroup reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
Citigroup sold 90,172 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $274K.
Citigroup first reported a position in Revance Therapeutics, Inc. in Q1 2014 and held it in 44 quarters.
Citigroup's Revance Therapeutics, Inc. position peaked at $1.92M in Q3 2022.
1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.